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Introduction
There is a mounting need for therapeutics to effectively
treat neurodegenerative diseases. Alzheimer's disease, Par-
kinson's disease, Huntington's disease, amyotrophic lat-
eral sclerosis, and multiple sclerosis almost all share
pathological hallmarks of accumulated misfolded pro-
tein, ultimately leading to cellular degeneration and death
[1]. There is much to be learned by the successes and fail-
ures of drug discovery efforts for these respective diseases.
Exciting and novel ideas from academia often fail to reach
drug discovery platforms and pharmaceutical companies
have had little success in their neurodegenerative disease
programs thus far; currently, only symptomatic treat-
ments are available for the majority of these diseases [2,3].
While these diseases present unique challenges in terms of
drug discovery, they also offer many opportunities to
change the way academics and industry work together to
efficiently develop new drugs. To bring new drugs into
clinical practice for neurodegenerative diseases, efforts to
translate academic discoveries into drug discovery and
development efforts can be expanded and partnering
between academic biologists, medicinal chemists and
industry researchers encouraged. Cross-fertilization of
ideas between these different neurodegenerative diseases
as well as between academia and industry will foster novel
developments and hopefully bring us closer to developing
effective treatments for these diseases.
These proceedings highlight new approaches to address
and overcome the specific challenges of drug discovery for
neurodegenerative diseases that were discussed at the 3rd
Drug Discovery for Neurodegenerative Conference (held
in Washington DC on 2–3 February 2009). This confer-
ence was hosted by the Alzheimer's Drug Discovery Foun-
dation, in partnership with the National Institutes of
Health, to advance drug discovery for neurodegenerative
diseases by educating scientists on the process of translat-
ing basic research into novel therapies. Over the two day
conference, speakers presented lectures and case studies
on Alzheimer's disease, Parkinson's disease, Huntington's
disease, amyotrophic lateral sclerosis, multiple sclerosis,
as well as orphan neurological diseases. All of these dis-
eases share common challenges and require a broad and
coordinated, multi-disciplinary approach to progress
novel discoveries into effective therapeutics.
Basics of medicinal chemistry
Medicinal chemistry is an essential piece to the drug dis-
covery puzzle and was highlighted in the first session of
the conference. This session was chaired by Dr Martin
Watterson (Northwestern University) and included talks
on the fundamentals of drug discovery chemistry and how
later-stage considerations of pharmacokinetics, patho-
physiology and production must be considered early on,
at the medicinal chemistry stage. Dr Alan Kozikowski
(University of Illinois) reminded participants that intui-
from Drug Discovery for Neurodegeneration Conference
Washington, DC, USA. 2–3 February 2009
Published: 12 June 2009
BMC Neurology 2009, 9(Suppl 1):I1 doi:10.1186/1471-2377-9-S1-I1
<supplement> <title> <p>Proceedings of the 2009 Drug Discovery for Neurodegeneration Conference</p> </title> <editor>Diana W Shineman and Howard M Fillit</editor> <sponsor> <note>The conference and the publication of these proceedings were supported by conference grant U13-AG031125 from the National Institute on Aging, the National Institute of Neurological Disorders and Stroke and the National Institutes of Health's Office of Rare Diseases. Other sponsors: CoMentis, Eli Lilly and Company, sanofi-aventis, Biogen Idec and The Michael J. Fox Foundation for Parkinson's Research</note>  </sponsor> <note>Proceedings</note> <url>http://www.biomedcentral.com/content/pdf/1471-2377-9-S1-info.pdf</url> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2377/9/S1/I1
© 2009 Shineman and Fillit; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2009, 9(Suppl 1):I1 http://www.biomedcentral.com/1471-2377/9/S1/I1
Page 2 of 3
(page number not for citation purposes)
tion plays an important role in medicinal chemistry as
well and biologists need to work in partnership with
medicinal chemists in a coordinated effort. The impor-
tance of patents and intellectual property in medicinal
chemistry was also discussed. Rick Silverman (Northwest-
ern University) discussed a case study of developing selec-
tive neuronal nitric oxide synthase inhibitors [4]. Drs
Frank Longo (Stanford University) and Jordan Tang
(Oklahoma Medical Research Foundation) also presented
fascinating case studies about developing drugs to target
key pathways in neurodegenerative diseases. Frank Longo
discussed virtual library screening and his experience
developing peptidomimetic compounds [5], while Jordan
Tang used his expertise on matrix metalloproteases to
develop novel and specific inhibitors of beta-secretase [6].
Finally, Dr Chris Lipinski (Melior Discovery) closed the
session with a discussion on selection of candidates for
drug development, emphasizing that his 'Lipinski Rule of
5' criteria should be used as guidelines and not as stead-
fast rules.
Hits and leads: early phases of drug discovery
Marcie Glicksman (Harvard Medical School) discussed
common pitfalls in high-throughput development and
emphasized the importance of developing high quality
secondary screens. This point was also emphasized by Dr
Linda VanEldik (Northwestern University), who dis-
cussed the utility of also performing secondary screens to
determine ADMET (absorption, distribution, metabolism
and excretion, and toxicology) properties and noted that
many of these screens are commercially available. Most
drug development efforts fail due to toxicity and ADMET
properties and Dr Karen Steinmetz (SRI International)
went into more detail on some of the technologies for
ADMET screening, discussed common pitfalls and
emphasized the need to consider the future plan of clini-
cal administration at the onset of screening. An in-depth
review of ADMET considerations in drug discovery is pre-
sented in these proceedings by Katya Tsaioun (Apredica).
Pre-clinical proof-of-concept and development
Once a drug-candidate has been identified, pre-clinical
proof-of-concept and drug development studies are initi-
ated, as described by Edward Spack (SRI International) at
the conference and as presented here in these proceedings.
In transitioning from lead compound to clinical testing,
William Banks (Saint Louis University) discussed preclin-
ical proof-of-concept and the challenges of the blood-
brain barrier in central nervous system drug discovery, as
well as methods to improve central nervous system expo-
sure. A review of characteristics of compounds that cross
the blood-brain barrier is presented by Dr Banks in these
proceedings. In addition, Nancy Wehner (Elan Pharma-
ceuticals) discussed the requirements that lead com-
pounds should meet before becoming 'clinical
candidates' and emphasized that outsourcing pre-clinical
studies is often needed to efficiently move a compound
forward. Daniela Brunner (PsychoGenics, Inc.) discussed
behavioral testing in neurodegenerative diseases from a
drug screening perspective [7]. Finally, partnership oppor-
tunities are often crucial to moving clinical candidates for-
ward into human testing. Thomas Argentieri (Wyeth)
addressed what decisions may support or hinder pharma
partnership opportunities. He stressed the importance of
intellectual property position and discussed the major
attributes companies look for in a partner.
Issues in technology transfer: interactions and 
intellectual property
The importance of protecting intellectual property posi-
tion was echoed in a session chaired by Kathleen Denis
(Rockefeller University). This session began with an intro-
duction on the various roles and responsibilities of the
tech transfer office as well as the basics of patents and
what they can and cannot successfully cover. The require-
ments for patentability were further outlined by Colin
Sandercock (Proskauer Rose LLP). Louis Berneman (Tex-
elerate) then went on to discuss patent licensing and
material transfer agreements as ways for academics to cre-
ate and foster relationships with industry that are benefi-
cial to both parties. Finally, John Swartley (University of
Pennsylvania) closed the session with an assessment of
the positives and negatives of starting a biotechnology
company, stressing the importance of managing expecta-
tions and setting realistic company goals.
Resources and services for advancing drug 
discovery
The final session of the conference focused on resources
and services available for advancing drug discovery and
included talks on the scientific and funding resources
available. These mechanisms include those within
academia (as presented by Martin Watterson), within the
National Institutes of Health (as presented by Suzana
Petanceska and Lorenzo Refolo), through disease-specific
foundation resources, and through commercial vendors
(as presented by Katya Tsaioun, Apredica). Speakers
focused on resources for assay development, target identi-
fication, drug discovery, drug development, pre-clinical
toxicology evaluation and other components needed for
the translation of pre-clinical drug candidates into poten-
tial therapies tested in clinical trials. The final panel dis-
cussed the role of venture philanthropy in funding drug
discovery for neurodegenerative disorders. Philanthropies
are able to take on more risk and fund novel high risk
approaches that would be less likely to be funded through
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Conclusion
This conference provided ample networking opportuni-
ties for scientists from academia, biotechnology compa-
nies, and contract research organizations to meet, discuss
ideas and foster collaborations. Through continued edu-
cation and the nurturing of interdisciplinary interactions,
we will be able to overcome the unique challenges of drug
discovery for neurodegenerative disease and develop
effective therapies to meet the growing need for treat-
ments.
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